|
||
| |||||||
|
|
Successful platform now offers
even more comprehensive ADME Optimisation
London, UK, March 14, 2006 - Inpharmatica Ltd., the selective drug discovery company, today releases new editions of Admensa Interactive(TM), its compound optimisation platform, including unique compound prioritisation tools and an in silico suite of predictive drug absorption, distribution, metabolism and excretion (ADME) models. The new editions respond to market demands for tools that group together even more effectively key elements of compound optimisation. Since its launch in 2005, Admensa Interactive has attracted a strong global customer base, with installations at five of the top 20 pharma companies.
The new versions of Admensa
Interactive now available for on-site installation are;
- ADME Edition - includes a
range of rigorously validated high throughput ADME QSAR models for desktop
installation,
- P450 Edition - provides
unique quantum based models predicting sites of P450 metabolism on chemical
compounds,
- Professional Edition -
combines both the ADME QSAR and P450 quantum models for complete virtual ADME
optimisation.
The intuitive Admensa Interactive interface can objectively evaluate extensive libraries of structures and compare individual compounds, based on a wide range of compound properties, either virtual or synthesised, to aid effective decision making. Data from experiments or users' own in-house models can be incorporated in this environment. Users can manipulate individual compound structures in real-time to explore individual ADME properties or overall compound quality.
Admensa Interactive is an integral
component of Inpharmatica's gene-to-candidate technology platform which
integrates biology- and chemistry-based drug discovery activities. This
platform optimises target selection based on druggability, and enables rapid
identification of hits and selection of high quality leads and pre-clinical
candidates, which are prioritised on the basis of good drug-like
characteristics and clinical indication.
Commenting on the release, John
Lisle, Inpharmatica's CEO, said: "These new editions of Admensa Interactive
are a direct response to user feedback on one of our most successful
offerings. We expect these enhancements both to provide even better solutions
for our pharmaceutical and biotechnology customers' discovery needs, and to
reinforce Inpharmatica's leading position in the marketplace."
For more information on
gaining access to Admensa Interactive and its capabilities, please visit
www.inpharmatica.co.uk/AdmensaInteractive.htm.
About Inpharmatica:
www.inpharmatica.com/admensa.htm
Founded in 1998, Inpharmatica uses
predictive informatics in genomics, medicinal chemistry and ADME to improve
the speed and productivity of drug discovery. The company employs around 90
professionals at its UK locations in London and Cambridge, with business
development in North America and Japan. Inpharmatica's unique proprietary
technologies and skills are utilised in major discovery laboratories worldwide
including Serono, Pfizer, GSK, Novartis, Sanofi-Aventis, P&G Pharmaceuticals,
and Daiichi.
Inpharmatica is unique in offering
discovery technologies and services which span the full breadth of research
from gene through to candidate selection: the core elements are fully
integrated, enabling customers to access the full end-to-end technologies, or
individual components and services as required.
For more information, please
contact:
Andrew Lloyd & Associates
Andrew Lloyd / Heidi Thompson
Tel: +44 1273 675100
Inpharmatica Ltd
John Lisle, Chief Executive Officer Tel: +44 (0)20 7074 4600 Dr Vimal Mehta, Sr. VP Business Development
Tel: +1 203 453 6525
|
|
| ||||||||
